1 week ago

Vir Biotechnology (VIR) Stock Jumps 13% After Phase 3 Hepatitis Delta Win

TLDR Vir Biotechnology stock rose 13% to $13.85 on Monday. Phase 3 ECLIPSE 1 met its primary and key secondary endpoints. 44% of treated patients had undetectable virus and normal ALT at Week 48, versus 0% for delayed treatment. One Grade 3 treatment-related event was reported, and no patient stopped treatment. Phase 2 SOLSTICE data [...]

The post Vir Biotechnology (VIR) Stock Jumps 13% After Phase 3 Hepatitis Delta Win appeared first on Blockonomi.

Source: Blockonomi →